QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: Recombinant Factor VIII Classification, Mechanism, Inhibitors and Pharmacovigilance

Test your understanding of the concepts covered by Recombinant Factor VIII: Classification, History, Mechanism of Action, Inhibitors and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which historical interpretation of recombinant FVIII development is most accurate?

Recombinant manufacture was developed partly in response to historical blood-borne virus transmission concerns, but current recombinant products are not risk-free The history of plasma-derived products proves that all current plasma-derived products have the same risk profile The first recombinant FVIII products were approved before molecular cloning enabled recombinant production Recombinant production eliminated the need for biological quality control

Question 2 of 10 Why is a Bethesda-based inhibitor titre alone insufficient to characterise an FVIII inhibitor case?

Bethesda assays measure only platelet function Titre does not by itself establish the clinical effect, recovery or half-life of FVIII in that patient A Bethesda result is meaningful only for acquired haemophilia Inhibitor titres are unrelated to neutralisation of FVIII

Question 3 of 10 Which case would most clearly require investigation of possible inhibitor development?

A patient has a brief delay in infusion but achieves expected haemostasis A patient has recurrent bleeding and unexpectedly poor FVIII recovery despite verified dosing and administration A patient reports mild anxiety before an infusion with no change in FVIII response A patient receives a product within its labelled storage conditions and has no clinical event

Question 4 of 10 Which statement best reflects the interpretation of thromboembolic events during FVIII treatment?

Thrombosis is impossible in congenital haemophilia A Any thrombotic event proves that FVIII caused the event Thrombotic risk may increase with factors such as excessive replacement, surgery, immobilisation, central access, age or comorbidity Thrombotic events are relevant only in acquired haemophilia

Question 5 of 10 A patient switches from one recombinant FVIII product to another and later develops an unexpected recovery pattern. Which pharmacovigilance approach is best?

Discard all pre-switch information because only the current product is relevant Compare the complete before-and-after product, batch, exposure, assay, recovery, inhibitor and clinical-response history Assume the switch caused the event because it preceded the observation Compare only the products' nominal FVIII strengths

Question 6 of 10 Which case description provides the most useful basis for evaluating apparent lack of efficacy with recombinant FVIII?

The report states only that 'factor VIII was given and bleeding continued' The report includes exact product and batch, dose and timing, exposure days, assay method, recovery, inhibitor testing and clinical bleeding outcome The report includes only the patient's age and sex The report includes only a single post-treatment FVIII activity value

Question 7 of 10 Which statement about women and girls with haemophilia A is most appropriate for pharmacovigilance and clinical assessment?

The label 'carrier' establishes normal FVIII activity Female patients cannot develop clinically relevant haemophilia A phenotypes Factor level, bleeding phenotype, genotype and reproductive context should be assessed individually Only genetic status matters; bleeding history is not relevant

Question 8 of 10 Which information is most important when assessing a suspected immediate hypersensitivity reaction to recombinant FVIII?

Only the patient's historical inhibitor titre The immediate clinical phenotype, product and batch, device, infusion rate, treatment and any re-exposure outcome Only the interval since the last joint bleed The patient's prophylaxis schedule without details of the infusion

Question 9 of 10 Which manufacturing change would most appropriately trigger regulatory comparability consideration?

A change in manufacturing site, cell bank, purification process, formulation or analytical method A change in the patient's target joint A change in the wording of a spontaneous case narrative A change in the patient's home infusion appointment

Question 10 of 10 Which statement best describes the relationship between regulatory comparability assessment and pharmacovigilance?

Pharmacovigilance replaces the need for quality comparability assessment A temporal cluster alone proves diminished biological comparability Comparability assessment evaluates manufacturing-related quality changes, while pharmacovigilance detects unexpected clinical patterns and helps investigate their significance Neither process is relevant to biological medicines after authorisation

QPPV.com

Knowledge Assessment: Recombinant Factor VIII Classification, Mechanism, Inhibitors and Pharmacovigilance

Cookie Settings